(+/-)-cis-3-(hydroxymethyl)cyclohexanol | 15753-48-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (+/-)-cis-3-(hydroxymethyl)cyclohexanol
• 英文别名: (1S,3R)-3-(hydroxymethyl)cyclohexan-1-ol
• CAS: 15753-48-7
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: PFXRPUFYSLHDMF-RQJHMYQMSA-N

物化性质

• 熔点：
  181 °C(Solv: 1,4-dioxane (123-91-1))
• 沸点：
  200 °C(Press: 0.3 Torr)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+/-)-cis-3-(hydroxymethyl)cyclohexanol 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.25h， 生成 cis-3-(tert-butyldiphenylsilyloxymethyl)cyclohexyl (R)-(-)-α-methoxy-α-(trifluoromethyl)phenylacetate
  参考文献：
  名称：

  Siglec-8 配体 6'-Sulfo-Sialyl Lewisx 的有效模拟物。

  摘要：

  Siglecs 是含有唾液酸结合 N 端结构域的免疫球蛋白基因家族的成员。其中，Siglec-8 在免疫系统的各种细胞类型上表达，如嗜酸性粒细胞、肥大细胞和弱碱性粒细胞。Siglec-8 与单克隆抗体的交联触发嗜酸性粒细胞凋亡并抑制肥大细胞脱颗粒，使 Siglec-8 成为治疗嗜酸性粒细胞和肥大细胞相关疾病（如哮喘）的有希望的靶点。四糖 6'-磺基唾液酸路易斯x已被鉴定为聚糖阵列筛选中的特定 Siglec-8 配体。在这里，我们描述了一项扩展研究，启发了 6'-磺基-唾液酸路易斯x的药效团并成功开发了一种高亲和力的模拟物。保留神经氨酸核心，在 9 位引入 Gal 部分的碳环模拟物和磺酰胺取代基使结合亲和力提高了 20 倍。最后，停留时间，通常是碳水化合物/凝集素相互作用的跟腱，可以得到改善。

  DOI：

  10.1002/cmdc.202000417
• 作为产物：
  描述：

  间羟基苯甲酸 在 sodium hydroxide 、 lithium aluminium tetrahydride 、 镍 、 奎宁 作用下， 生成 (+/-)-cis-3-(hydroxymethyl)cyclohexanol
  参考文献：
  名称：

  Studies of Configuration. I. The Configurations of the 3-Methylcyclohexanols^*

  摘要：

  DOI：

  10.1021/ja01143a024

文献信息

• Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20040122069A1

  公开（公告）日：2004-06-24

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披露了二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。这些化合物包括式I,1中定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物通常具有降脂和/或三酸甘油酯降低作用，并且适用于例如治疗脂质代谢紊乱、II型糖尿病和X综合征等疾病。
• Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
  申请人：——

  公开号：US20030144332A1

  公开（公告）日：2003-07-31

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披萨店的员工们正在忙着准备今晚的外卖订单。
• Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040198786A1

  公开（公告）日：2004-10-07

  Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals The invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula 1, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  环烷基衍生物具有生物等效羧酸基团，其制备方法及其作为药物的用途。本发明涉及具有生物等效羧酸基团的环烷基衍生物及其生理上可接受的盐和生理功能衍生物。所描述的化合物具有下式1,1中所定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用障碍以及胰岛素抵抗相关的紊乱。
• 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209932A1

  公开（公告）日：2004-10-21

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  本发明涉及具有酸性、大多数是杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能衍生物。所描述的是式I中的化合物，其中基团如定义所示，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病。
• 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Goerlitzer Jochen

  公开号：US20080249126A1

  公开（公告）日：2008-10-09

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.

  本发明涉及具有酸性、大多数为杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能性衍生物。所描述的是式I的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备它们的方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及涉及胰岛素抵抗的紊乱。